Your Position:

Reported by PR Newswire published

2022.12.17

Reported by PR Newswire published-Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD toEvaluate DR30303 in Combination with KEYTRUDAR® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer

Zhejiang Doer Biologics Co.,Ltd.

Telephone:0571-28256206

Fax:0571-28256206

Email:bd@doerbio.com

Address:Floor 2,Building 3, Hexiang Science and Technology Center, Phase 3, Medicine Port Town, Qiantang New District, Hangzhou,Zhejiang Province

© 2016-2020 Zhejiang Doer Biologics Co.,Ltd. Copyright Record number:网站备案号：浙ICP备14037239号

Scan to follow us